The Clinical Research On The Efficacy Of GDP Regimen On Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Objective: To research on the clinical efficacy and the toxicity of GDP regimen on relapsed or refractory aggressive non-Hodgkin's lymphoma.Methods: Patients with relapsed or refractory aggressive non-Hodgkin's Lymphoma (NHL) are taken the GDP regimen (gemcitabine 1000 mg/m2 on Day 1 and Day 8, dexamethasone 40mg/ day on Day 1 to Day 4, and daunorubicinum 20-30mg/m2 on Day 1 to Day 3) every three weeks for one cycle, and it will be evaluated the efficacy in two consecutive cycles. The efficacy evaluation is measured using solid tumor evaluation criteria. Twenty patients are analyzed by the indicators such as ORR(overall response rate), CBR(clinical beneficial rate ), OS(overall survival), TTP(time to progression), the adverse effects rate and so on.Results: Of twenty assessable patients with the treatment of 4.4 cycles, thirteen ones had response, including that three had complete response, ten had partial response, five had stable disease, and two had progressive disease. The overall response rate was 65.0%, the clinical beneficial rate was 90.0%, one-year overall survival was 70.0%, the median of time to progression was 9.5 months (4-5 months). Patients with elevation of plasma LDH were significantly decreased compared with before and after treatment (p=0.0001). The adverse effects of Chemotherapy toxicity were mainly mild gastrointestinal effects and bone marrow toxicity: the decreased incidence rates of leukocyte and platelets were 75% and 30%, the toxic incidence rates of leukocyte and platelets 40% and 50%; there were obvious no heart and hepatorenal harm, no treatment-related death.Conclusion: GDP regimen, whose toxicity most patients can afford, is an effective and relatively salvage chemotherapy regimen for relapsed or refractory aggressive NHL with a good short-term effect, and it is a remedy with further validation.